Please assess the completion status of the following clinical trial:

Trial Title: A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a live twin living in the same household who is also enrolled in this study.~* Born after a gestation period of ≥32 weeks,~* Discharged from hospital neonatal care stay,~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 6 and 14 weeks of age at the time of the first study vaccination.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Written informed consent obtained from the parent or guardian of the subjects.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* Any clinically significant history of chronic gastrointestinal disease.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Acute disease at time of enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Contact with an immunosuppressed individual.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Chronic administration of immunosuppressants since birth.~* Gastroenteritis within 7 days preceding the first study vaccine administration.~* Documented HIV-positive subject.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 14 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix Group (Type: EXPERIMENTAL): All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3).
- Placebo Group (Type: PLACEBO_COMPARATOR): All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3).

Based on this trial design, predict the completion outcome and termination type (if applicable).